Nurix Therapeutics, Inc. entered into Amendment No. 3 to its Equity Distribution Agreement with Piper Sandler & Co. on March 6, 2026, increasing the aggregate offering amount to $413.65 million of common stock through at-the-market offerings pursuant to its Automatic Shelf Registration Statement. Fenwick & West LLP provided a legal opinion confirming the shares will be validly issued, fully paid, and nonassessable.
Key takeaways
Entered Amendment No. 3 to Equity Distribution Agreement on March 6, 2026 with Piper Sandler
Aggregate gross offering price increased to $413,650,000 of common stock ($0.001 par value)
Includes shares sold after Amendment No. 2 on October 31, 2024
Sales through at-the-market offerings as sales agent
Prospectus Supplement Amendment No. 1 filed March 6, 2026 under Registration Statement File No. 333-280117
Legal opinion from Fenwick & West LLP filed as Exhibit 5.1